Overview Request Sample Pages Request Customization Download PDF
You are viewing: Australia Preimplantation Genetic Testing Market analysis

The Australia Preimplantation Genetic Testing Market was valued at $4.2 Million in 2025 and projected to reach to $6.7 Million by 2030, representing a compound annual growth rate of 9.9%. Australia's Preimplantation Genetic Testing market is positioned for steady growth as fertility awareness increases and reproductive healthcare becomes more accessible across the country.

Australia Preimplantation Genetic Testing Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Australia Preimplantation Genetic Testing Market Trends and Insights

  • Australia's fertility sector is increasingly adopting PGT technologies to enhance reproductive outcomes and reduce genetic disease transmission.
  • The market growth in Australia is driven by rising awareness among couples, improved access to assisted reproductive technologies, and supportive regulatory frameworks that encourage genetic screening adoption. In Australia, the demand for PGT services reflects broader trends in personalized medicine and preventive healthcare.
  • Between 2025 and 2030, Australia's market will benefit from technological advancements, growing fertility clinic infrastructure, and increasing consumer acceptance of genetic testing.
  • Australia's healthcare system and private fertility sector are well-positioned to support this expansion, with established clinical protocols and trained specialists driving market penetration across major metropolitan areas..

Key Market Statistics

  • CAGR (2025-2030) 9.9% CAGR
  • Market Size, 2025 ~USD 4.2 Million
  • Forecast, 2030 ~USD 6.7 Million
  • Country Australia

Australia Preimplantation Genetic Testing Market Overview

Market Valuation :

Australia's Preimplantation Genetic Testing market is valued at $4.2 million in 2025, with projections to reach $6.7 million by 2030, representing a robust 9.9% CAGR.

Fertility Sector Adoption :

Australian fertility clinics are increasingly integrating PGT technologies to improve reproductive outcomes and minimize the risk of genetic disease transmission to offspring.

Growth Drivers :

Rising consumer awareness, improved healthcare accessibility, and growing acceptance of assisted reproductive technologies are key factors propelling market expansion across Australia.

Competitive Landscape :

Australia's PGT market features a mix of established diagnostic providers and emerging fertility technology companies competing to capture growing demand from fertility centers nationwide.

Australia Preimplantation Genetic Testing Market Dynamics

  • The 9.9% CAGR reflects growing adoption among Australian couples seeking advanced genetic screening options to ensure healthy pregnancies and reduce hereditary disease risks.
  • Increasing investment in fertility infrastructure and rising disposable incomes support market expansion.
  • By 2030, the market is expected to reach $6.7 million, driven by technological advancements, regulatory support, and enhanced clinical outcomes.
  • Australian fertility centers are prioritizing PGT integration to remain competitive and meet patient expectations for comprehensive reproductive health solutions..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    Biotechnology

    Top Technologies
    • Reagents
    • Polymerase Chain Reaction (PCR)
    • Stem Cells
    • Assay Kits
    • Flow Cytometers
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.

      Key Takeaways

      • Australia's PGT market is valued at $4.2 million in 2025 and will reach $6.7 million by 2030, representing a 9.9% CAGR.
      • Australia's fertility clinics are increasingly integrating PGT into standard assisted reproductive protocols to improve success rates.
      • Rising consumer awareness and acceptance of genetic screening in Australia is a primary driver of market expansion through 2030.
      • Australia's regulatory environment and healthcare infrastructure support sustained growth in PGT adoption across the country.

      Preimplantation Genetic Testing Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment SINGLE GENE DISORDERS (Application)
      Forecast Period 2025–2030
      Growth Rate CAGR of 10.5% from 2025 to 2030
      Largest Segment PREIMPLANTATION GENETIC SCREENING (Procedure Type)
      Market Size Base Year (Billions) ~USD 0.69 (2025)
      Revenue Forecast (Billions) ~USD 1.14 (2030)
      Segments Covered Product & Service, Procedure Type, Technology, Application, Type, Type Of Cycle, End User

      Australia Preimplantation Genetic Testing Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Product & Service

      • Instruments
      • Reagents & Consumables
      • Software & Services

      By Procedure Type

      • Preimplantation Genetic Diagnosis
      • Preimplantation Genetic Screening

      By Technology

      • Comparative Genomic Hybridization
      • Fluorescence In Situ Hybridization
      • Next-Generation Sequencing
      • Polymerase Chain Reaction
      • Single-Nucleotide Polymorphism

      By Application

      • Aneuploidy
      • Gender Identification
      • Hla Typing
      • Single Gene Disorders
      • Structural Chromosomal Abnormalities
      • X-Linked Disorders

      By Type

      • Deletions
      • Duplications
      • Inversions
      • Translocations

      By Type Of Cycle

      • Fresh Donor
      • Fresh Non-Donor
      • Frozen Donor
      • Frozen Non-Donor

      By End User

      • Diagnostic Laboratories
      • Fertility Clinics
      • Hospitals
      • Other End Users

      AUSTRALIA: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030

      Segment20232024202520262027202820292030CAGR (%)
      DIAGNOSTIC LABORATORIES1.11.181.291.411.551.711.892.110.3
      FERTILITY CLINICS3.153.363.633.964.334.765.245.789.7
      HOSPITALS0.790.840.890.971.051.141.241.368.7
      OTHER END USERS0.310.320.340.370.40.430.470.57.9
      TOTAL5.345.716.166.77.338.048.849.749.6

      Target Audience

      • Fertility Clinic Operators : Australian fertility centers need market data to assess PGT service demand, benchmark adoption rates, and plan technology investments to enhance reproductive outcomes and patient satisfaction.
      • Diagnostic & Biotech Companies : PGT service providers and genetic testing companies require Australia-specific market intelligence to identify growth opportunities, competitive positioning, and clinical partnership potential.
      • Healthcare Investors & PE Firms : Investment professionals evaluating Australian fertility and reproductive health opportunities need localized market sizing and growth forecasts to support due diligence and portfolio decisions.
      • Medical Device & Technology Vendors : Companies developing PGT platforms and laboratory automation solutions need Australia market insights to prioritize regional expansion, assess addressable market, and guide product development.
      • Healthcare Policy & Regulatory Bodies : Australian health authorities and policy makers require market data to inform reimbursement policies, clinical guidelines, and regulatory frameworks governing PGT accessibility and quality standards.

      Key Companies in the Australia Preimplantation Genetic Testing Market

      CompanyHQOwnershipStrongest segments
      CIMARON LABELPressure-sensitive paper labels,Film and durable labels,Specialty/custom applications,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLaboratory Products and Biopharma Services,Life Sciences Solutions,Analytical Instruments,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      REVVITYUnited StatesPublic CompanyReagents, Assays, and Consumables,Instruments and Detection/Imaging Platforms,Software, Subscriptions, and Informatics,
      COOPERCOMPANIESUnited StatesPublic CompanySpherical contact lenses,Toric and multifocal contact lenses,Fertility consumables, equipment, and services,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      TAKARA BIO INC.JapanPrivate CompanyResearch reagents for genetic and cellular research,Instruments (PCR instruments and cellular analysis devices),In vitro diagnostics (including COVID-19 testing),
      VITROLIFESwedenPublic CompanyIVF media and oil,Labware (dishes, pipettes, tubes, VitroTemp, eWitness-related consumables),Cryopreservation solutions,

      CIMARON LABEL

      Insufficient information provided to generate description.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. The company is a global leader in serving science, providing laboratory equipment, reagents, and analytical instruments.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company provides life sciences, diagnostics, and applied chemical markets with instruments and software.

      REVVITY

      Revvity is a United States-based public company founded in 1937 with 11,000 employees. The company provides analytical technologies and solutions for research, diagnostics, and applied markets.

      COOPERCOMPANIES

      CooperCompanies is a United States-based public company founded in 1958 with 15,000 employees. The company operates in the medical device sector, primarily focused on contact lenses and eye care products.

      ABBOTT

      Abbott is a United States-based public company founded in 1888 with 115,000 employees. The company is a diversified healthcare manufacturer producing pharmaceuticals, diagnostics, nutritional products, and medical devices.

      TAKARA BIO INC.

      Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees. The company specializes in biotechnology research and development.

      VITROLIFE

      Vitrolife is a Sweden-based public company founded in 1989 with 1,103 employees. The company develops and manufactures products for assisted reproduction and embryo culture.

      Reasons to Buy this Report

      • Australia-Specific Market Sizing : Obtain precise valuation data for Australia's PGT market with verified 2025 baseline ($4.2M) and 2030 forecast ($6.7M), enabling accurate business planning and investment decisions.
      • Regional Growth Trajectory : Understand Australia's 9.9% CAGR performance relative to global 10.5% growth, identifying localized opportunities and competitive advantages within the Australian fertility sector.
      • Fertility Sector Insights : Access detailed analysis of PGT adoption patterns among Australian fertility clinics, patient demographics, and clinical implementation trends specific to the Australian healthcare environment.
      • Strategic Market Entry : Leverage Australia-focused competitive intelligence and market dynamics to develop targeted go-to-market strategies for fertility technology providers, diagnostic companies, and healthcare investors.
      • Regulatory & Healthcare Context : Gain insights into Australia's regulatory framework, healthcare reimbursement landscape, and clinical guidelines governing PGT adoption to inform compliance and commercialization strategies.

      Frequently asked questions

      What is the current market size of PGT in Australia?

      Australia's Preimplantation Genetic Testing market is valued at $4.2 million in 2025.

      What is the projected market size for PGT in Australia by 2030?

      Australia's PGT market is forecast to reach $6.7 million by 2030.

      What is the growth rate of the PGT market in Australia?

      Australia's PGT market is expected to grow at a compound annual growth rate of 9.9% between 2025 and 2030.

      What factors are driving PGT market growth in Australia?

      Key drivers in Australia include rising consumer awareness, improved fertility clinic infrastructure, supportive regulatory frameworks, and increasing acceptance of genetic screening technologies.

      How does Australia's PGT market compare to global trends?

      Australia's 9.9% CAGR is slightly below the global average of 10.5%, reflecting a mature but steadily expanding market with strong healthcare infrastructure.

      RESEARCH METHODOLOGY

      This research extensively used secondary sources, directories, and databases to gather valuable information for analyzing the global preimplantation genetic testing market. In-depth interviews were conducted with various primary respondents, including key industry players, subject-matter experts (SMEs), C-level executives, and industry consultants, to obtain and verify important qualitative and quantitative data and evaluate the market’s growth prospects. The global market size estimated through secondary research was cross-checked with inputs from primary research to determine the final market size.

      Secondary Research

      Secondary research was mainly used to gather information for the detailed technical, market, and commercial analysis of the preimplantation genetic testing market. The secondary sources for this study include the World Health Organization (WHO), World Bank, Human Fertilization and Embryology Authority (HFEA), International Federation of Fertility Societies (IFFS), American Society for Reproductive Medicine (ASRM), Australia and New Zealand Assisted Reproduction Database (ANZARD), Centers for Disease Control and Prevention (CDC), Society for Assisted Reproductive Technology (SART), National Health Service (NHS), Indian Fertility Society (IFS), British Fertility Society (BFS), European Society of Human Reproduction and Embryology (ESHRE), Association for Fertility and Reproductive Health (AFRH), German Society of Reproductive Medicine (DGRM), Canadian Fertility & Andrology Society (CFAS), Indian Society for the Study of Reproduction and Fertility (ISSRF), Spanish Fertility Society (Sociedad Española de Fertilidad-SEF), Japan Society for Reproductive Medicine, National Registry of Assisted Reproductive Technology and Surrogacy Registry, Journal of Human Reproductive Sciences, American Congress of Obstetricians and Gynecologists (ACOG), European Society of Human Genetics (ESHG); ACS Journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.

      Secondary data was collected and analyzed to determine the overall size of the global preimplantation genetic testing market, which was then validated through primary research. These sources also provided key information about major players, market classification, and segmentation based on industry trends, regional and country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

      Preimplantation Genetic Testing Market

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the preimplantation genetic testing market. These methods were also used extensively to estimate the size of various market segments.

      Preimplantation Genetic Testing Market

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.

      Market Definition

      Preimplantation genetic testing (PGT) examines embryos during in vitro fertilization (IVF) before possible transfer to a woman's uterus. This is done to test a range of genetic problems that can cause implantation failure, miscarriage, and birth defects in a resulting child.

      Preimplantation genetic testing refers to the three types of tests that may be performed on embryos during IVF:

      • Preimplantation genetic screening for abnormal chromosome number (PGT-A)
      • Preimplantation genetic testing for monogenic (individual) disease (PGT-M)
      • Preimplantation genetic testing structural rearrangement (PGT-SR) for known chromosomal misarrangements such as inversion and translocation.

      The study offers an in-depth analysis of the preimplantation genetic testing market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key preimplantation genetic testing product and service providers.

      Stakeholders

      • Contract research organizations (CROs)
      • Contract development and manufacturing organizations (CDMOs)
      • In vitro fertilization (IVF) centers and fertility clinics
      • Life science companies
      • Fertility clinics
      • Academic & research institutes
      • Private research institutes
      • Venture capitalists & investors
      • Market research & consulting firms
      • Government associations
      • Medical institutions & universities
      • Hospitals & clinics

      Report Objectives

      • To define, describe, and forecast the preimplantation genetic testing market based on procedure type, technology, product & service, application, type of cycle, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall preimplantation genetic testing market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the preimplantation genetic testing market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the preimplantation genetic testing market
      • To benchmark players within the preimplantation genetic testing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy

      Get the Full Preimplantation Genetic Testing Market Report

      Full forecast, segment splits, and company analysis for all Preimplantation Genetic Testing Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status